{
  "id": 3930360,
  "title": "Samsung Biologics announces 3 trillion won rights offering for expansion",
  "url": "https://urgent.news/2026/08/28/samsung-biologics-announces-3-trillion-won-rights-offering-for",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-28T08:56:08.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/samsung-biologics-announces-3-trillion-won-rights-offering-for-expansion-159651.html"
  },
  "original_language": "en",
  "account": "Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced on August 28, 2026, its intent to raise KRW 3 trillion through a rights offering. The funds will be used to fuel the company's three-dimensional growth strategy in capacity, portfolio, and geographic expansion.\n\nApproximately KRW 2.71 trillion of the offering proceeds are earmarked for the acquisition of PolyPeptide Group, a significant stride towards broadening the company's portfolio into peptide-based therapeutics. The remaining KRW 290 billion will be allocated to the expansion of Bio Campus II, a strategic move to enhance the company's manufacturing capabilities.\n\nJohn Rim, President and CEO of Samsung Biologics, expressed confidence in their ability to execute this three-pronged growth strategy, positioning the company for a stronger leadership role and enduring shareholder value. The rights offering involves the issuance of approximately 2,270,000 new common shares at a price of KRW 1,322,000 each, which is around 15% lower than the reference price.\n\nThe total funds raised are estimated to account for roughly 4.90% of the company's current market capitalization. Subscribers include existing shareholders on a pro-rata basis, with any unsubscribed shares subject to a general public offering. Of the new shares, 20% will be designated for Samsung Biologics' employee stock ownership plan, with the rest offered to shareholders proportionally.",
  "summary": "Biotechnology provider Samsung Biologics launched a 3 trillion Korean won rights offering to fund long term manufacturing capacity expansion and broaden its global production portfolio",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BusinessKorea",
        "title": "Samsung Biologics Bets on Peptides with Trillion-Won Rights Offering",
        "url": "https://urgent.news/2026/08/28/samsung-biologics-bets-on-peptides-with-trillion-won-rights-offering",
        "published": "2026-08-28T08:44:16.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}